CHU de Québec Collaborates with PerkinElmer on a study funded by Genome Canada, Génome Québec, CIHR and Genome Alberta using DNA sequencing alone or in a contingent model with first trimester serum markers as non-invasive option to determine risk of Down
A team of clinical researchers led by CHU de Québec has received CAN$10.5 million from Génome Québec, Genome Canada, CIHR, Genome Alberta and other partners to recruit 5,600 pregnant women in Canada to study the potential of using DNA sequencing alone or in a contingent model with first trimester serum markers as a non-invasive method